jyongbio.com - רווח החברה לפני מסים, ריבית ופחת MENS

The specific nature of the botanical R&D cycle complicates drug releases, yet success in urology and expense control maintain the stability of Jyong Biotech Ltd (MENS). Absolute EBITDA reflects current cash flow dynamics, where the parameter value reaches 0.00. These figures are based on the development of safe plant-based medications for prostate treatment without side effects.

This indicator tracks daily cash flow from core operations before depreciation, interest, and taxes, allowing for an assessment of the business's actual operational efficiency. By analyzing the level of net operating income before depreciation, an investor can see the ability of Jyong Biotech Ltd (MENS) to fund its R&D team and hire compliance specialists using its own resources without increasing its debt load.